• Afatinib (BIBW 2992): Precision Tools for Dissecting Tumor-S

  2026-06-20

  Explore how Afatinib (BIBW 2992) empowers researchers to unravel tumor-stroma interactions and EGFR pathway resistance in advanced cancer models. This in-depth guide delivers actionable insights beyond standard protocols for cancer biology research.

• PHF2 Histone Demethylase Orchestrates Neuroinflammation in A

  2026-06-19

  The reference study identifies PHF2 as a central epigenetic regulator of inflammatory gene expression in Alzheimer’s disease (AD). Knockdown of PHF2 in AD models reduces neuroinflammatory signaling and restores cognitive function, highlighting PHF2 as a promising therapeutic target for neurodegenerative disorders involving inflammation.

• Cyclophosphamide: Applied Workflows for Cancer Research Succ

  2026-06-19

  Cyclophosphamide is a gold-standard alkylating chemotherapeutic agent, enabling precise apoptosis induction and immune modulation in both cancer and transplantation models. This guide delivers practical workflow enhancements, troubleshooting strategies, and comparative insights for maximizing reproducibility and translational value.

• Mubritinib (TAK 165) in AML & HER2 Research: Protocols & Pit

  2026-06-18

  Mubritinib (TAK 165) is transforming cancer and virology research by precisely inhibiting mitochondrial complex I, revealing metabolic vulnerabilities in chemotherapy-resistant AML. This article delivers practical workflows, troubleshooting insights, and protocol parameters to help researchers maximize Mubritinib's unique applications in AML, HER2-driven cancer biology, and PEL models.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme (E1): Bench

  2026-06-18

  This article provides scenario-driven guidance for biomedical researchers using PYR-41, inhibitor of Ubiquitin-Activating Enzyme (E1) (SKU B1492), with a focus on reproducibility, protocol optimization, and data interpretation in ubiquitin-proteasome system assays. Drawing on validated data and recent literature, it delivers actionable insights to ensure robust cell viability and inflammation models.

• 3X (DYKDDDDK) Peptide: Optimizing FLAG Tag Workflows in Rese

  2026-06-17

  The 3X (DYKDDDDK) Peptide empowers sensitive, high-yield affinity purification and immunodetection for recombinant protein studies, with unmatched flexibility in structural biology and metal-dependent assays. Discover how its unique design and robust performance, as provided by APExBIO, unlock next-level troubleshooting and workflow reproducibility.

• Simvastatin (Zocor) in Lipidomics & Cancer Research Workflow

  2026-06-17

  Simvastatin (Zocor) from APExBIO stands out in both cholesterol and hepatic cancer research by enabling precise, reproducible modulation of lipid metabolism and cell fate. This article translates cutting-edge lipidomics and apoptosis evidence into actionable lab workflows, with troubleshooting insights for optimal assay performance.

• UBE2F-SAG–Mediated RHEB Neddylation Drives mTORC1 in Liver C

  2026-06-16

  This study reveals that RHEB is neddylated by the UBE2F-SAG axis, promoting mTORC1 activation and exacerbating liver tumorigenesis. The mechanistic insight into RHEB modification adds a new layer to mTORC1 regulation and highlights potential therapeutic targets for hepatocellular carcinoma.

• Optimizing Cardiomyopathy Models with Norepinephrine Bitartr

  2026-06-16

  (-)-Norepinephrine (+)-bitartrate from APExBIO empowers researchers to rapidly induce and modulate cardiovascular disease models with precision, thanks to its well-characterized receptor selectivity and reproducible vasoconstrictive actions. This guide unpacks advanced in vivo and in vitro workflows, troubleshooting strategies, and the translational impact of recent clinical dosing insights.

• Deracoxib–Doxorubicin Combination: Cytoprotection in Canine

  2026-06-15

  This study reveals that Deracoxib, a selective COX-2 inhibitor, reduces the cytotoxic and pro-apoptotic effects of doxorubicin in normal canine mammary epithelial cells in vitro. The findings highlight a mechanistic link between nitric oxide modulation and cell survival, suggesting a potential strategy for minimizing chemotherapy toxicity in veterinary oncology.

• mCherry mRNA (5mCTP, ψUTP): Precision Reporter for Immune-Ev

  2026-06-15

  Explore how mCherry mRNA empowers robust, immune-evasive fluorescent protein expression. This article offers a scientific deep dive into mRNA engineering, practical assay design, and the latest insights on enhancing mRNA stability and translation.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-14

  Schwartz's dissertation redefines the assessment of anti-cancer drugs by rigorously separating cell proliferation arrest from cell death in in vitro assays. This nuanced approach offers researchers clearer mechanistic insights and enhances the predictive value of preclinical drug evaluation, supporting more rational experimental design in cancer biology.

• Cell Counting Kit-8 (CCK-8): Advancing Ferroptosis and Hepat

  2026-06-13

  Explore the unique role of Cell Counting Kit-8 (CCK-8) in precise cell viability measurement within ferroptosis and liver toxicity models. This article offers actionable insights for researchers seeking advanced applications and decision-making in toxicology and hepatocyte biology.

• Telmisartan: Advancing Cardiac Hypertrophy Research Precisio

  2026-06-12

  This article explores Telmisartan’s mechanistic role as an angiotensin II receptor antagonist in experimental and translational cardiovascular research. We examine emerging insights from necroptosis signaling studies, highlight rigorous protocol considerations, and provide strategic guidance for researchers leveraging Telmisartan to model and counteract maladaptive cardiac remodeling.

• Melatonin Inhibits RIPK3-Mediated Necroptosis in Atrazine Ki

  2026-06-12

  This study identifies melatonin as a potent inhibitor of necroptosis in atrazine-induced kidney damage, acting through the RIPK1–RIPK3–MLKL pathway. The findings clarify melatonin's molecular mechanism and highlight its therapeutic potential for chemical-induced nephrotoxicity.

406 records 11/28 page Previous Next First page 上5页 1112131415 下5页 Last page